Nuvation Bio Inc. Selling, General and Administrative Expense
Nuvation Bio Inc. (NUVB) reported Selling, General and Administrative Expense of $42.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Nuvation Bio Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $42.59M, a 10.67% increase year-over-year.
- Nuvation Bio Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $38.31M, a 8.24% increase year-over-year.
- Nuvation Bio Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $40.33M, a 54.28% increase year-over-year.
- Nuvation Bio Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $37.36M, a 90.78% increase year-over-year.
- Nuvation Bio Inc. selling, general and administrative expense for fiscal 2025 was $151.56M, a 118.92% increase from fiscal 2024.
- Nuvation Bio Inc. selling, general and administrative expense for fiscal 2024 was $69.23M, a 142.64% increase from fiscal 2023.
- Nuvation Bio Inc. selling, general and administrative expense for fiscal 2023 was $28.53M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.59M 10-Q · filed 2026-08-06 | $80.90M 10-Q · filed 2026-08-06 | $121.23M derived: sum of 3 quarters · filed 2026-08-06 | $158.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $38.31M 10-Q · filed 2026-05-04 | $78.64M derived: sum of 2 quarters · filed 2026-05-04 | $115.99M derived: sum of 3 quarters · filed 2026-05-04 | $154.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $40.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $77.69M derived: sum of 2 quarters · filed 2026-03-02 | $116.17M derived: sum of 3 quarters · filed 2026-08-06 | $151.56M 10-K · filed 2026-03-02 |
| 2025-09-30 | $37.36M 10-Q · filed 2025-11-03 | $75.84M derived: sum of 2 quarters · filed 2026-08-06 | $111.24M 10-Q · filed 2025-11-03 | $137.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $38.48M 10-Q · filed 2026-08-06 | $73.88M 10-Q · filed 2026-08-06 | $100.02M derived: sum of 3 quarters · filed 2026-08-06 | $119.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $35.39M 10-Q · filed 2026-05-04 | $61.53M derived: sum of 2 quarters · filed 2026-05-04 | $81.11M derived: sum of 3 quarters · filed 2026-05-04 | $97.27M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $26.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $45.72M derived: sum of 2 quarters · filed 2026-03-02 | $61.88M derived: sum of 3 quarters · filed 2026-03-02 | $69.23M 10-K · filed 2026-03-02 |
| 2024-09-30 | $19.58M 10-Q · filed 2025-11-03 | $35.74M derived: sum of 2 quarters · filed 2025-11-03 | $43.09M 10-Q · filed 2025-11-03 | $48.58M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $16.16M 10-Q · filed 2025-08-07 | $23.51M 10-Q · filed 2025-08-07 | $28.99M derived: sum of 3 quarters · filed 2025-08-07 | $36.77M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $7.36M 10-Q · filed 2025-05-07 | $12.84M derived: sum of 2 quarters · filed 2025-05-07 | $20.61M derived: sum of 3 quarters · filed 2025-05-07 | $28.16M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $13.26M derived: sum of 2 quarters · filed 2025-03-06 | $20.80M derived: sum of 3 quarters · filed 2025-03-06 | $28.53M 10-K · filed 2025-03-06 |
| 2023-09-30 | $7.78M 10-Q · filed 2024-11-06 | $15.32M derived: sum of 2 quarters · filed 2024-11-06 | $23.05M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $7.54M 10-Q · filed 2024-08-05 | $15.28M 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |